Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Interleukin-36 gamma (IL-36γ) is a pro-inflammatory cytokine belonging to the interleukin-1 family. It is primarily expressed in epithelial tissues, particularly in the skin, gut, and lung. IL-36γ binds to the IL-36 receptor (IL1RL2) and requires IL-1RAcP for signaling, leading to the activation of NF-κB and MAPK pathways and the production of pro-inflammatory cytokines and chemokines. It plays a critical role in innate immune responses and is strongly implicated in chronic inflammatory diseases such as psoriasis and inflammatory bowel disease. The activity of IL-36γ is specifically inhibited by the interleukin-36 receptor antagonist (IL-36Ra).
Inhibition of IL-36 receptor signaling by IL-36Ra
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interleukin-36 gamma (IL-36γ).